Guillermo Villacampa

Guillermo Villacampa

Auto-generated profile, based on publicly available information

Guillermo Villacampa

Statistical Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MCMarta Castroviejo‐Bermejo
Marta Castroviejo‐Bermejo
CCCristina Cruz
Cristina Cruz
ALAlba Llop‐Guevara
Alba Llop‐Guevara
Sara Gutiérrez-EnríquezSara Gutiérrez-Enríquez
Sara Gutiérrez-Enríquez
MDMandy Ducy
Mandy Ducy
VSVioleta Serra
Violeta Serra
Poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are effective in cancers with defective homologous recombination DNA repair (HRR), including BRCA1/2‐related cancers. A test to identify additional HRR‐deficient tumors will help to extend their use in new indications. We evaluated the activity of the PARPi olaparib in patient‐derived tumor xenografts (PDXs) from breast cancer (BC) patients and investigated mechanisms of sensitivity through exome sequencing, BRCA1 promoter methylation analysis, and immunostaining of HRR proteins, including RAD51 nuclear foci. In an independent BC PDX panel, the predictive capacity of the RAD51 score and the homologous recombination deficiency (HRD) score were compared. To examine the clinical feasibility of the RAD51 assay, we scored archival breast tumor samples, including PALB2‐related hereditary cancers. The RAD51 score was highly discriminative of PARPi sensitivity versus PARPi resistance in BC PDXs and outperformed the genomic test. In clinical samples, all PALB2‐related tumors were classified as HRR‐deficient by the RAD51 score. The functional biomarker RAD51 enables the identification of PARPi‐sensitive BC and broadens the population who may benefit from this therapy beyond BRCA1/2‐related cancers. Synopsis Sensitive and highly specific biomarkers usable in archived formalin fixed parafin embedded (FFPE) tumour samples are needed to extend the use of PARP inhibitors beyond BRCA1/2‐related cancers. The RAD51 score may satisfy this clinical unmet need. The RAD51 score shows complete discriminative capacity in predicting PARP inhibitor response. The RAD51 score is feasible in routine breast tumor samples without prior exposure to DNA damaging agents. Carrying a PALB2 mutation is associated with a low RAD51score.

1 October 2019 in Annals of Oncology
Verified
Journal Article
Open access
RDR. Dienstmann
R. Dienstmann
GVG. Villacampa
G. Villacampa
ASA. Sveen
A. Sveen
MMM.J. Mason
M.J. Mason
DND. Niedzwiecki
D. Niedzwiecki
JGJ. Guinney
J. Guinney
It remains unknown to what extent consensus molecular subtype (CMS) groups and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor-node-metastasis (TNM) staging and microsatellite instability (MSI) status in early-stage colorectal cancer (CRC). We carried out a comprehensive retrospective biomarker analysis of prognostic markers in adjuvant chemotherapy-untreated (N = 1656) and treated (N = 980), stage II (N = 1799) and III (N = 837) CRCs. We defined CMS scores and estimated CD8+ cytotoxic lymphocytes (CytoLym) and cancer-associated fibroblasts (CAF) infiltration scores from bulk tumor tissue transcriptomes (CMSclassifier and MCPcounter R packages); constructed a stratified multivariable Cox model for disease-free survival (DFS); and calculated the relative proportion of explained variation by each marker (clinicopathological [ClinPath], genomics [Gen: MSI, BRAF and KRAS mutations], CMS scores [CMS] and microenvironment cells [MicroCells: CytoLym+CAF]). In multivariable models, only ClinPath and MicroCells remained significant prognostic factors, with both CytoLym and CAF infiltration scores improving survival prediction beyond other markers. The explained variation for DFS models of ClinPath, MicroCells, Gen markers and CMS4 scores was 77%, 14%, 5.3% and 3.7%, respectively, in stage II; and 55.9%, 35.1%, 4.1% and 0.9%, respectively, in stage III. Patients whose tumors were CytoLym high/CAF low had better DFS than other strata [HR=0.71 (0.6-0.9); P = 0.004]. Microsatellite stable tumors had the strongest signal for improved outcomes with CytoLym high scores (interaction P = 0.04) and the poor prognosis linked to high CAF scores was limited to stage III disease (interaction P = 0.04). Our results confirm that tumor microenvironment infiltration patterns represent potent determinants of the risk for distant dissemination in early-stage CRC. Multivariable models suggest that the prognostic value of MSI and CMS groups is largely explained by CytoLym and CAF infiltration patterns.

1 April 2021 in Radiology
Verified
Journal Article
Closed access
MLMarta Ligero
Marta Ligero
AGAlonso Garcia-Ruiz
Alonso Garcia-Ruiz
CVCristina Viaplana
Cristina Viaplana
GVGuillermo Villacampa
Guillermo Villacampa
MRMaria V. Raciti
Maria V. Raciti
RPRaquel Perez-Lopez
Raquel Perez-Lopez
A CT-based radiomics signature, based on histogram, shape, and local-regional texture features, showed an association with immune response in advanced solid tumors. Background Reliable predictive imaging markers of response to immune checkpoint inhibitors are needed. Purpose To develop and validate a pretreatment CT-based radiomics signature to predict respons...

20 June 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
GIGloria Iacoboni
Gloria Iacoboni
KRKai Rejeski
Kai Rejeski
GVGuillermo Villacampa
Guillermo Villacampa
JDJaap A. van Doesum
Jaap A. van Doesum
ACAnnalisa Chiappella
Annalisa Chiappella
PBPere Barba
Pere Barba
Gloria Iacoboni, Kai Rejeski, Guillermo Villacampa, Jaap A. van Doesum, Annalisa Chiappella, Francesca Bonifazi, Lucia Lopez-Corral, Michiel van Aalderen, Mi Kw

15 April 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
IMIgnacio Matos
Ignacio Matos
JMJuan Martin-Liberal
Juan Martin-Liberal
AGAlonso García-Ruiz
Alonso García-Ruiz
CHCinta Hierro
Cinta Hierro
MOMaria Ochoa de Olza
Maria Ochoa de Olza
EGElena Garralda
Elena Garralda
Purpose: Most hyperprogression disease (HPD) definitions are based on tumor growth rate (TGR). However, there is still no consensus on how to evaluate this phenomenon. Patients and Methods: We investigated two independent cohorts of patients with advanced solid tumors treated in phase I trials with (i) programmed cell death 1 (PD-1)/PD-L1 antibodies in monotherapy or combination and (ii) targeted agents (TA) in unapproved indications. A Response Evaluation Criteria in Solid Tumors (RECIST) 1.1–based definition of hyperprogression was developed. The primary endpoint was the assessment of the rate of HPD in patients treated with ICIs or TAs using both criteria (RECIST and TGR) and the impact on overall survival (OS) in patients who achieved PD as best response. Results: Among 270 evaluable patients treated with PD-1/PD-L1 inhibitors, 29 PD-1/PD-L1–treated patients (10.7%) had HPD by RECIST definition. This group had a significantly lower OS (median of 5.23 months; 95% CI, 3.97–6.45) when compared with the non-HPD progressor group (median, 7.33 months; 95% CI, 4.53–10.12; HR = 1.73, 95% CI, 1.05–2.85; P = 0.04). In a subset of 221 evaluable patients, 14 (6.3%) were categorized as HPD using TGR criteria, differences in median OS (mOS) between this group (mOS 4.2 months; 95% IC, 2.07–6.33) and non-HPD progressors (n = 44) by TGR criteria (mOS 6.27 months; 95% CI, 3.88–8.67) were not statistically significant (HR 1.4, 95% IC, 0.70–2.77; P = 0.346). Among 239 evaluable patients treated with TAs, 26 (10.9%) were classified as having HPD by RECIST and 14 using TGR criteria in a subset of patients. No differences in OS were observed between HPD and non-HPD progressors treated with TAs. Conclusions: HPD measured by TGR or by RECIST was observed in both cohorts of patients; however, in our series, there was an impact on survival only in the immune-checkpoint inhibitor cohort when evaluated by RECIST. We propose a new way to capture HPD using RECIST criteria that is intuitive and easy to use in daily clinical practice.

1 July 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
JRJordi Remon
Jordi Remon
MAMyung-Ju Ahn
Myung-Ju Ahn
NGNicolas Girard
Nicolas Girard
MJMelissa Johnson
Melissa Johnson
DKDong-Wan Kim
Dong-Wan Kim
QZQing Zhou
Qing Zhou